We are enhancing the body’s natural immune defenses to specifically target solid and hematologic cancers by optimizing the binding of T-cells and their receptors such that they can recognize cancer cells and clear them from the body.
Once we have affinity-enhanced a TCR, we can deliver it to patients through a robust and commercializable manufacturing process. To manufacture our TCR therapeutic candidates, we collect blood cells from a cancer patient using a process called leukapheresis. CD4 (helper T-cells) and CD8 (cytotoxic T-cells) cells are isolated from the white blood cells. We then deliver the genes encoding the affinity-enhanced TCRs to the T-cells.
These affinity enhanced T-cells are then expanded through a process using DynaBeads® CD3/CD28 beads which provide healthier cells and more robust expansion compared to other validated expansion methods. The cells are then concentrated and frozen until the patient is ready to receive them.
We continue to make a number of enhancements to the vector and cell processing as we further develop our TCR therapeutic candidates. We are investing substantially in a manufacturing process that we believe is efficient and commercially scalable.